Jan 12 2010
Pluristem
Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced
interim results from their Phase I clinical trials utilizing their
placenta derived cell therapy product, PLX-PAD, for the treatment of
critical limb ischemia (CLI), the end-stage of peripheral artery disease
(PAD). Data suggested that PLX-PAD is safe and potentially efficacious.
“The interim results
are a significant milestone for Pluristem as we advance in our Phase I
clinical trials to further test the safety and potential efficacy of
PLX-PAD.”
Nine patients, representing one-third of the patients needed to complete
the Phase I dose-escalating studies in the U.S. and Germany, have been
dosed with PLX-PAD. Patients experienced no significant unfavorable
effects related to PLX-PAD administration. Three of the nine patients
dosed completed their three-month follow up and the data from those
patients demonstrated a trend towards efficacy with a reduction in their
Rutherford Category, a measure of the severity of their limb ischemia.
“The interim results are in line with the data from the first patient
treated with PLX-PAD,” said Professor Doctor André Schmidt-Lucke,
Director of the Franziskus-Krankenhaus Institute of Berlin, Germany. “We
are encouraged by the consistency of the data and believe that PLX-PAD
may be an effective treatment for CLI.”
Zami Aberman, chairman and CEO of Pluristem, added, “The interim results
are a significant milestone for Pluristem as we advance in our Phase I
clinical trials to further test the safety and potential efficacy of
PLX-PAD.”
http://www.pluristem.com/